Barclays
NVNO

Barclays’s enVVeno Medical NVNO Stock Holding History

Barclays’s Portfolio NVNO Stock Details NVNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21 Buy
+2
New +$22 ﹤0.01% 5285
2020
Q1 		– Hold
0
– – – 6362
2019
Q4 		– Hold
0
– – – 6663

Other funds holding NVNO

KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Barclays's NVNO Position: Q2 2026 in Review

Barclays opened a new position in enVVeno Medical (NVNO) in Q2 2026: 2 shares worth $21. The stake represents ﹤0.01% of the portfolio and ranks #5285 among its holdings.

17 funds tracked by Wall St. Rank hold NVNO as of Q2 2026.

  • Barclays held 2 shares of enVVeno Medical worth $21 as of Q2 2026.
  • enVVeno Medical was a new Barclays position in Q2 2026.
  • enVVeno Medical made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5285 holding.
  • 17 funds tracked by Wall St. Rank held enVVeno Medical as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.